Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 10/20 | 0.68 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.60 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.60 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.60 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.58 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6152306 | 0.86 | OPRL1 (0.54) | GRIN2BGRIN2DGRIN3BCYP2D6GRIN1 | |
| SCHEMBL6902857 | 0.86 | OPRL1 (0.54) | GRIN2BOPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL6690779 | 0.84 | GRIN2B (0.50) | GRIN2BOPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL6151725 | 0.84 | GRIN2B (0.50) | GRIN2BOPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL6152148 | 0.84 | GRIN2B (0.50) | GRIN2BOPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL8857324 | 0.83 | OPRL1 (0.51) | GRIN2BOPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL7330603 | 0.82 | OPRL1 (0.50) | GRIN2BGRIN2DGRIN3BCYP2D6GRIN1 | |
| SCHEMBL8857496 | 0.81 | GRIN2B (0.70) | GRIN2BGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL16608330 | 0.81 | GRIN2B (1.00) | GRIN2B | |
| SCHEMBL16601285 | 0.81 | GRIN2B (1.00) | GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743921-B2 | HYDROGENATION OF A CORRESPONDING NONRACEMIC 1-(4-BENZOXY PHENYL)-2-(4-HYDROXY-4-PHENYL-PIPERIDIN-1-YL)-1-PROPANONE USING A CATALYST SYSTEM COMPRISING RUTHENIUM, A NONRACEMIC DIPHOSPHINE LIGAND, A BIDENTATE AMINE LIGAND SELECTED FROM | DSM CATALYTICA PHARMACEUTICALS, INC. | 2004-06-01 | — | — | US | claimed |
| US-20030144521-A1 | Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl -piperidin-1-yl)-1-propanol compounds | DSM CATALYTICA PHARMACEUTICALS, INC. | 2003-07-31 | — | — | US | claimed |
| WO-2003062180-A1 | PROCESS FOR THE PREPARATION OF NONRACEMIC SYN-1-(4-HYDROXY-PHENYL)-2-(4-HYDROXY-4-PHENYL-PIPERIDIN-1-YL)-1-PROPANOL COMPOUNDS | DSM N.V. (NL) | 2003-07-31 | — | — | WO | claimed |
| EP-1497245-A1 | PROCESS FOR THE PREPARATION OF NONRACEMIC SYN-1-(4-HYDROXY-PHENYL)-2-(4-HYDROXY-4-PHENYL.PIPERIDIN-1Yl)-1-PROPANOL COMPOUNDS | DSM Pharmaceuticals, Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-6743921-B2 | HYDROGENATION OF A CORRESPONDING NONRACEMIC 1-(4-BENZOXY PHENYL)-2-(4-HYDROXY-4-PHENYL-PIPERIDIN-1-YL)-1-PROPANONE USING A CATALYST SYSTEM COMPRISING RUTHENIUM, A NONRACEMIC DIPHOSPHINE LIGAND, A BIDENTATE AMINE LIGAND SELECTED FROM | DSM CATALYTICA PHARMACEUTICALS, INC. | 2004-06-01 | — | — | US | disclosed |
| US-20030144521-A1 | Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl -piperidin-1-yl)-1-propanol compounds | DSM CATALYTICA PHARMACEUTICALS, INC. | 2003-07-31 | — | — | US | disclosed |
| WO-2003062180-A1 | PROCESS FOR THE PREPARATION OF NONRACEMIC SYN-1-(4-HYDROXY-PHENYL)-2-(4-HYDROXY-4-PHENYL-PIPERIDIN-1-YL)-1-PROPANOL COMPOUNDS | DSM N.V. (NL) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003062181-A1 | PROCESS FOR THE PREPARATION OF NONRACEMIC SYN-1-(4-HYDROXY-PHENYL)-2-(4-HYDROXY-4-PHENYL.PIPERIDIN-1Yl)-1-PROPANOL COMPOUNDS | DSM PHARMACEUTICALS, INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| US-5696126-A | Prodrug esters of phenolic 2-piperidino-1-alkanols | PFIZER INC. (US) | 1997-12-09 | — | — | US | disclosed |
| US-5654302-A | Prodrug esters of phenolic 2-piperidino-1-alkanols | PFIZER INC. (US) | 1997-08-05 | — | — | US | disclosed |
| US-5594007-A | Method for treating spinal cord trauma with phenolic 2-piperidino-1-alkanols | PFIZER INC. (US) | 1997-01-14 | — | — | US | disclosed |
| US-5455250-A | Prodrug esters of phenolic 2-piperidino-1-alkanols | PFIZER INC. (US) | 1995-10-03 | — | — | US | disclosed |
| EP-0584192-A1 | PRODRUG ESTERS OF PHENOLIC 2-PIPERIDINO-1-ALKANOLS | PFIZER INC. (US) | 1994-03-02 | — | — | EP | disclosed |
| WO-1992018502-A1 | PRODRUG ESTERS OF PHENOLIC 2-PIPERIDINO-1-ALKANOLS | PFIZER INC. (US) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144521-A1 | Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl -piperidin-1-yl)-1-propanol compounds | SYNJ1, HRH4, HRH3 | GRIN2B 2908/4885GRIN2D 2117/4885GRIN3B 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.